Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

[up] Up a level
Number of items: 30.

Versluis, Jurjen, Metzner, Marlen, Wang, Ariel, Gradowska, Patrycja, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Rachel, Boertjes, Emma, Vonk, Christian M., Kavelaars, Francois G., Rijken, Melissa, Gilkes, Amanda, Schwab, Claire, Beverloo, H. Berna, Manz, Markus, Visser, Otto, Van Elssen, Catharina H.M.J., de Weerdt, Okke, Tick, Lidwine W., Biemond, Bart J., Vekemans, Marie-Christiane, Freeman, Sylvie D., Harrison, Christine J., Cook, Jonathan A., Dennis, Mike, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Thomas, Ian, Craddock, Charles, Ossenkoppele, Gert J., Löwenberg, Bob, Russell, Nigel, Valk, Peter J.M. and Vyas, Paresh 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42 (34) , pp. 4084-4094. 10.1200/JCO.23.02631
file

Russell, Nigel H., Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Hills, Robert K., Thomas, Ian, Gilkes, Amanda, Marquez Almuina, Nuria, Burns, Sarah, Marsh, Lucy, Vyas, Paresh, Metzner, Marlen, McCarthy, Nicholas, Andrew, Georgia, Byrne, Jennifer, Sellar, Rob S., Kelly, Richard, Cahalin, Paul, Malthe Overgaard, Ulrik, Mehta, Priyanka, Dennis, Mike, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441 and Freeman, Sylvie D. 2024. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 10.1200/JCO.24.00259
filefile

Voso, Maria Teresa, Guarnera, Luca, Lehmann, Sören, Döhner, Konstanze, Döhner, Hartmut, Platzbecker, Uwe, Russell, Nigel H., Dillon, Richard James, Thomas, Ian, Ossenkoppele, Gert J, Haferlach, Torsten, Vignetti, Marco, La Sala, Edoardo, Piciocchi, Alfonso, Fazi, Paola, Villaverde Ramiro, Ángela, Tur Giménez, Laura, Gurnari, Carmelo, Bullinger, Lars and Hernandez, Jesus M. 2024. Acute promyelocytic leukemia: Long-term outcomes from the HARMONY project. Blood 10.1182/blood.2024026186

Rodríguez-Arbolí, Eduardo, Othus, Megan, Freeman, Sylvie D., Buccisano, Francesco, Ngai, Lok Lam, Thomas, Ian, Palmieri, Raffaele, Cloos, Jacqueline, Johnson, Sean, Meddi, Elisa, Russell, Nigel H., Venditti, Adriano, Gradowska, Patrycja, Ossenkoppele, Gert J., Löwenberg, Bob and Walter, Roland B. 2024. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) [Letter to the Editor]. Leukemia 38 (10) 10.1038/s41375-024-02378-5
filefilefile

Othman, Jad, Potter, Nicola, Ivey, Adam, Tazi, Yanis, Papaemmanuil, Elli, Jovanovic, Jelena, Freeman, Sylvie D., Gilkes, Amanda Frances, Gale, Rosemary E., Rapoz-D'Silva, Tanya, Runglall, Manohursingh, Kleeman, Michelle, Dhami, Pawan, Thomas, Ian, Johnson, Sean, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Cavenagh, James Durrell, Kottaridis, Panagiotis, Arnold, Claire, Ommen, Hans Beier, Overgaard, Ulrik Malthe, Dennis, Mike, Burnett, Alan Kenneth, Wilhelm-Benartzi, Charlotte S. ORCID: https://orcid.org/0000-0003-4927-6158, Huntly, Brian J.P., Russell, Nigel H. and Dillon, Richard James 2024. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 144 (7) , pp. 714-728. 10.1182/blood.2024024310
Item availability restricted.
file

Othman, Jad, Potter, Nicola, Ivey, Adam, Jovanovic, Jelena, Runglall, Manohursingh, Freeman, Sylvie D., Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Cavenagh, Jamie, Kottaridis, Panagiotis, Arnold, Claire, Ommen, Hans Beier, Overgaard, Ulrik Malthe, Dennis, Mike, Burnett, Alan, Wilhelm-Benartzi, Charlotte, Dillon, Richard and Russell, Nigel H. 2024. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143 (19) , pp. 1931-1936. 10.1182/blood.2023023096
file

Copland, Mhairi, Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Thomas, Ian F., Upton, Laura, Sydenham, Mia, Mehta, Priyanka, Islam, Shahid, Kjeldsen, Lars, Burnett, Alan K., Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Russell, Nigel, Dennis, Mike and UK NCRI AML Study Group 2024. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 204 (3) , pp. 871-876. 10.1111/bjh.19220
file

Kitson, Terri ORCID: https://orcid.org/0000-0001-6333-046X, Osborne, Emma, Noble, Simon ORCID: https://orcid.org/0000-0001-5425-2383, Pease, Nikki, Alikhan, Raza, Bryant, Catherine, Groves, Tristan, Wallace, Rebecca, Walker, Sarah, Seddon, Kathy, Smith, Deb, Raisanen, Lawrence, Smith, Joanna ORCID: https://orcid.org/0000-0003-4234-6686, Thomas, Ian, Upton, Laura and Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052 2023. HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care. BMJ Open 13 (9) , e073049. 10.1136/bmjopen-2023-073049
file

Mussai, Francis, De Santo, Carmela, Cheng, Paul, Thomas, Ian F., Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Upton, Laura, Scarpa, Ugo, Stavrou, Victoria, Sydenham, Mia, Burnett, Alan K., Knapper, Steven K. ORCID: https://orcid.org/0000-0002-6405-4441, Mehta, Priyanka, McMullin, Mary F., Copland, Mhairi, Russell, Nigel H. and Dennis, Mike 2023. A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial. British Journal of Haematology 200 (5) , pp. 573-578. 10.1111/bjh.18560
file

Loo, Sun, Dillon, Richard, Ivey, Adam, Anstee, Natasha S, Othman, Jad, Tiong, Ing Soo, Potter, Nicola, Jovanovic, Jelena, Runglall, Manohursingh, Chua, Chong Chyn, Bajel, Ashish, Ritchie, David, Gray, Kelli, Yeoh, Zhi Han, McBean, Michelle, Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Russell, Nigel H and Wei, Andrew H. 2022. Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome [Letter]. Blood 140 (22) , pp. 2407-2411. 10.1182/blood.2022016567
file

Döhner, Konstanze, Döhner, Hartmut, Weber, Daniela, Kapp-Schwoerer, Silke, Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Potter, Nicola, Bevan, Yana, Othman, Jad, Russell, Nigel H., Röllig, Christoph, Thiede, Christian, Bornhaeuser, Martin, Oellerich, Thomas, Elder, Jenna, Carvajal, Luis A., To, Zung, DiMartino, Jorge and Dillon, Richard 2022. Analysis of patient-level data from 3 cooperative group trials confirms a survival advantage for NPM1m patients achieving MRD-negative CR after intensive induction. Blood 140 (S1) , pp. 6293-6294. 10.1182/blood-2022-159212

Freeman, Sylvie D, Thomas, Abin, Thomas, Ian, Vyas, Paresh, Gilkes, Amanda, Metzner, Marlen, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Amy, Marquez Almuina, Nuria, Burns, Sarah, King, Sophie, Andrew, Georgia M., Gallagher, Kathleen M.E., Sellar, Rob, Cahalin, Paul, Weber, Duruta, Dennis, Mike, Mehta, Priyanka, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441 and Russell, Nigel H. 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140 (S1) , pp. 532-533. 10.1182/blood-2022-162245

Love, Sharon B., Cafferty, Fay, Snowdon, Claire, Carty, Karen, Savage, Joshua, Pallmann, Philip ORCID: https://orcid.org/0000-0001-8274-9696, McParland, Lucy, Brown, Louise, Masters, Lindsey, Schiavone, Francesca, Hague, Dominic, Townsend, Stephen, Amos, Claire, South, Annabelle, Sturgeon, Kate, Langley, Ruth, Maughan, Timothy, James, Nicholas, Hall, Emma, Kernaghan, Sarah, Bliss, Judith, Turner, Nick, Tutt, Andrew, Yap, Christina, Firth, Charlotte, Kong, Anthony, Mehanna, Hisham, Watts, Colin, Hills, Robert, Thomas, Ian, Copland, Mhairi, Bell, Sue, Sebag-Montefiore, David, Jones, Robert, Parmar, Mahesh K B and Sydes, Matthew R 2022. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials 23 , 757. 10.1186/s13063-022-06680-4
file

Russell, Nigel H., Hills, Robert K., Kjeldsen, Lars, Clark, Richard E., Ali, Sahra, Cahalin, Paul, Thomas, Ian F. and Burnett, Alan K. 2022. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology 198 (3) , pp. 528-534. 10.1111/bjh.18195
file

Tazi, Yanis, Arango-Ossa, Juan E., Zhou, Yangyu, Bernard, Elsa, Thomas, Ian, Gilkes, Amanda, Freeman, Sylvie, Pradat, Yoann, Johnson, Sean J., Hills, Robert, Dillon, Richard, Levine, Max F., Leongamornlert, Daniel, Butler, Adam, Ganser, Arnold, Bullinger, Lars, Döhner, Konstanze, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Döhner, Hartmut, Campbell, Peter J., Burnett, Alan K., Dennis, Michael, Russell, Nigel H., Devlin, Sean M., Huntly, Brian J. P. and Papaemmanuil, Elli 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13 (1) , 4622. 10.1038/s41467-022-32103-8
file

Russell, Nigel H., Hills, Robert K., Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Thomas, Ian, Kjeldsen, Lars, Dennis, Mike, Craddock, Charles, Freeman, Sylvie, Clark, Richard E. and Burnett, Alan K. 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107 (7) , pp. 1518-1527. 10.3324/haematol.2021.279010
file

Coats, Thomas, Bean, Daniel, Basset, Aymeric, Sirkis, Tamir, Brammeld, Jonathan, Johnson, Sean, Thomas, Ian, Gilkes, Amanda, Raj, Kavita, Dennis, Mike, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Mehta, Priyanka, Khwaja, Asim, Hunter, Hannah, Tauro, Sudhir, Bowen, David, Jones, Gail, Dobson, Richard, Russell, Nigel and Dillon, Richard 2022. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology 196 (6) , pp. 1337-1343. 10.1111/bjh.18013
file

Stimpson, Madeleine L., Wolf, Julia S., Williams, Emily L., Lait, Philippa J. P., Schewitz?Bowers, Lauren P., Greenwood, Rosemary, Pell, Julie, Thomas, Ian, Lee, Richard W. J. and Bradbury, Charlotte A. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196 (4) , pp. 1113-1117. 10.1111/bjh.17884
filefile

Dennis, Mike, Thomas, Ian F., Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Upton, Laura, Burnett, Alan K., Gilkes, Amanda, Radia, Rohini, Hemmaway, Claire, Mehta, Priyanka, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Clark, Richard E., Copland, Mhairi, Russell, Nigel and Hills, Robert K. 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5 (24) , pp. 5621-5625. 10.1182/bloodadvances.2021005038
file

Bradbury, Charlotte A., Pell, Julie, Hill, Quentin, Bagot, Catherine, Cooper, Nichola, Ingram, Jenny, Breheny, Katie, Kandiyali, Rebecca, Rayment, Rachel, Evans, Gillian, Talks, Kate, Thomas, Ian and Greenwood, Rosemary 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385 (10) , pp. 885-895. 10.1056/NEJMoa2100596

Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Severinsen, Marianne, Hemmaway, Claire, Greaves, Paul, Clark, Richard, Copland, Mhairi and Russell, Nigel 2021. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. British Journal of Haematology 194 (2) , pp. 298-308. 10.1111/bjh.17501

Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Knapper, Stephen ORCID: https://orcid.org/0000-0002-6405-4441, Freeman, Sylvie, Huntly, Brian, Clark, Richard E., Thomas, Ian F., Kjeldsen, Lars, McMullin, Mary Frances, Drummond, Mark, Kell, Jonathan and Spearing, Ruth 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39 (8) , pp. 890-901. 10.1200/JCO.20.01170
file

Greenwood, Rosemary, Pell, Julie, Foscarini-Craggs, Paula, Wale, Katharine, Thomas, Ian and Bradbury, Charlotte 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21 (1) , 873. 10.1186/s13063-020-04798-x
file

Burnett, Alan K., Hills, R K ORCID: https://orcid.org/0000-0003-0166-0062, Nielsen, O J, Freeman, S, Ali, A, Cahalin, P, Hunter, A, Thomas, Ian and Russell, N H 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32 , pp. 2693-2714. 10.1038/s41375-018-0148-3
file

Freeman, Sylvie D., Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Virgo, Paul, Khan, Naeem, Couzens, Steve, Dillon, Richard, Gilkes, Amanda, Upton, Laura, Nielsen, Ove Juul, Cavenagh, James D., Jones, Gail, Khwaja, Asim, Cahalin, Paul, Thomas, Ian, Grimwade, Davied, Burnett, Alan K. and Russell, Nigel H. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36 (14) , pp. 1486-1497. 10.1200/JCO.2017.76.3425
file

Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Russell, Nigel, Gilkes, Amanda, Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Gale, Rosemary E., Cavenagh, James D., Jones, Gail, Kjeldsen, Lars, Grunwald, Michael R., Thomas, Ian, Konig, Heiko, Levis, Mark J. and Burnett, Alan K. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129 (9) , pp. 1143-1154. 10.1182/blood-2016-07-730648
file

Burnett, Alan, Cavenagh, Jamie, Russell, Nigel, Hills, Robert ORCID: https://orcid.org/0000-0003-0166-0062, Kell, Jonathan, Jones, Gail, Nielsen, Ove Juul, Khwaja, Asim, Thomas, Ian and Clark, Richard 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101 (6) , pp. 724-731. 10.3324/haematol.2016.141937
file

Burnett, A. K., Russell, N. H., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M.-F., Cahalin, P., Dennis, M., Friis, L., Thomas, Ian, Milligan, D. and Clark, R. E. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125 (25) , pp. 3878-3885. 10.1182/blood-2015-01-623447

Khan, Naeem, Freeman, Sylvie D., Virgo, Paul, Couzens, Steve, Richardson, Peter, Thomas, Ian, Grech, Angela, Vyas, Paresh, Grimwade, David, Russell, Nigel H., Burnett, Alan K. and Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170 (1) , pp. 80-84. 10.1111/bjh.13398

Dennis, M., Russell, N., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Hemmaway, C., Panoskaltsis, N., McMullin, M. F., Kjeldsen, L., Dignum, H., Thomas, Ian, Clark, R. E., Milligan, D. and Burnett, Alan 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125 (19) , pp. 2923-2932. 10.1182/blood-2014-10-608117

This list was generated on Tue Apr 1 05:43:27 2025 BST.


Maintained by Cardiff University Information Services